Table 2.

Associations of CAIDE Dementia Risk Score with neuroimaging biomarkers

	CAIDE Dementia		CAIDE Dementia Risk Score
	Risk Score		including APOE
	n	OR (95% CI)	n	OR (95% CI)
More pronounced deep WML	130	1.22 (1.05–1.43)	117	1.22 (1.06–1.40)
More pronounced periventricular WML	130	1.09 (0.97–1.25)	117	1.05 (0.93–1.18)
More pronounced MTA	131	1.09 (0.95–1.27)	118	1.15 (1.00–1.30)
Amyloid positivity on PIB-PET	48	1.03 (0.84–1.25)	47	1.13 (0.93–1.38)
Standardized β-coefficient (p-value)
Hippocampal volume	131	–0.28 (0.003)	118	–0.33 (0.001)
AD signature thickness	131	–0.19 (0.042)	118	–0.24 (0.02)
Total GM volume	131	–0.29 (0.001)	118	–0.26 (0.009)

OR and 95% CI from ordinal or binary logistic regressions with neuroimaging measures as outcomes:

• •Visually rated deep WML (3 groups by Fazekas scale of severity: 0 for n = 17 subjects; 1 for n = 71; and 2-3 for n = 43).
• •Visually rated periventricular WML (4 groups by Fazekas scale of severity: 0 for n = 25 subjects; 1 for n = 45; 2 for n = 36; and 3 for n = 25).
• •Visually rated MTA (3 groups by Scheltens scale of severity: 0–0.5 for n = 20 subjects, 1 for n = 67, and 1.5–3 for n = 45).
• •Amyloid accumulation on PIB-PET (negative n = 28 subjects, positive n = 20 subjects).

Standardized β-coefficients (p-values) from linear regressions with hippocampal and GM volume, and cortical thickness as outcomes. All analyses are adjusted for follow-up time and study site (except PIB-PET –scans conducted in one site). APOE, apolipoprotein E genotype; CAIDE, Cardiovascular Risk Factors, Aging and Dementia study; WML, white matter lesions; MTA, medial temporal atrophy; AD signature thickness, Alzheimer’s disease signature thickness, average of cortical thickness in entorhinal, inferior temporal, middle temporal, and fusiform regions; GM, gray matter.